Madrigal Pharmaceuticals (MDGL)

• Market cap: $10.6B
• 1 day: -1.92%
• 5 days: -2.7%
• 1 month: -5.91%
• 3 months: -9.75%
• 6 months: 24.43%
• Year to date: -21.75%
• 1 year: 32.13%
• 5 years: 285.94%
• 10 years: 5,966.71%
• Sector: Healthcare
• Industry: Biotechnology

About: Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.

Employees: 528